Rotstein, Benjamin


Benjamin Rotstein, PhD, is an Assistant Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa, and Director of the Molecular Imaging Probes and Radiochemistry Laboratory at the University of Ottawa Heart Institute.


Dr. Rotstein obtained his BSc from Dalhousie University and the University of King’s College in Halifax, NS, and his PhD in Organic Chemistry from the University of Toronto. His doctoral research focused on the reactivity of amphoteric molecules and their applications in macrocyclization of peptides. He then pursued postdoctoral training in radiochemistry and molecular imaging at Harvard Medical School and Massachusetts General Hospital, where he was promoted to faculty in 2015. During his postdoctoral work, he discovered spirocyclic iodonium ylides for radiofluorination and contributed to the development of new enzyme and receptor tracers for positron emission tomography.

Dr. Rotstein’s previous training was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) in the form of postgraduate scholarships and a Postdoctoral Fellowship. He has received Young Investigator Awards from the Society of Nuclear Medicine and Molecular Imaging as well as the Alzheimer’s Drug Discovery Foundation (ADDF). He has been a co-investigator on project grants from the ADDF and the Michael J. Fox Foundation for Parkinson’s Research.

Dr. Rotstein’s research is funded by the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, the Canadian Foundation for Innovation (CFI), the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Ontario Ministry of Research, Innovation and Science.

Research & Clinical Interests 

Research in the Molecular Imaging Probes and Radiochemistry Laboratory is directed towards the discovery of radiopharmaceuticals for both studying biochemical and pharmaceutical mechanisms in living systems and diagnosis of disease conditions. Specific cardiovascular imaging targets include biomarkers and therapeutic targets for atherosclerosis, arrhythmias, valve disease, and heart failure. In support of these goals the lab also develops innovative radiochemical methodologies for small molecule radiolabeling and bioconjugation with short-lived isotopes such as carbon-11 and fluorine-18.


See current publications list at PubMed.

Selected publications:

Share This